Fate Therapeutics, Inc. (FATE) Cash Flow Statement
Where FATE’s cash came from and went, 2025
December 31, 2025 · U.S. dollars- Cash from operations
- −$106.1M
- Capital expenditures
- $6.0M 89.6% of revenue
- Free cash flow
- −$112.0M −1,685.8% margin
- Returned to shareholders
- —
- Change in cash
- $10.6M cash at year-end $56.9M
Cash from operations
−$106.1M
Capital expenditures
−$6.0M
Investments (net)
+$116.8M
Other financing
+$5.5M
Change in cash
$10.6M
Drawn to scale: where the cash came from and how it was used. Hover for values.
FATE operating cash flow, capex and free cash flow
Operating cash flowCapital expendituresFree cash flowFCF margin (right axis)
FATE cash flow trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$29.8M2016 | −$106.1M2025 | — | |
| Capital expenditures | $457,0002016 | $6.0M2025 | +33.0%/yr | |
| Free cash flow | −$30.3M2016 | −$112.0M2025 | — | |
| Free cash flow margin | −687.9%2016 | −1,685.8%2025 | −997.9 pts | |
| Stock-based compensation | $3.2M2016 | $24.9M2025 | +25.7%/yr | |
| Dividends paid | $186,0002016 | $2.5M2019 | +138.5%/yr | |
| Share buybacks (net) | $02016 | $02021 | — | |
| Capex / revenue | 10.4%2016 | 89.6%2025 | +79.2 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
FATE cash flow by activity
OperatingInvestingFinancingChange in cash
FATE net income vs operating cash flow
Net incomeOperating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
FATE cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −$136.3M | −$186.3M | −$160.9M | −$281.7M | −$212.2M | −$173.4M | −$98.1M | −$66.6M | −$43.0M | −$33.5M |
| Depreciation & amortization | $9.3M | $19.0M | $18.3M | $13.8M | $5.8M | $3.1M | $2.2M | $1.2M | $971,000 | $881,000 |
| Stock-based compensation | $24.9M | $41.5M | $43.5M | $78.7M | $54.4M | $30.8M | $17.4M | $6.3M | $3.6M | $3.2M |
| Change in working capital | −$3.7M | −$2.0M | $19.2M | −$34.7M | $2.1M | −$12.8M | $3.6M | $1.7M | $2.1M | $1.2M |
| Other non-cash items | −$247,000 | $4.9M | −$52.3M | −$24.3M | −$13.0M | $113.1M | −$8.3M | $18.7M | −$613,000 | −$1.6M |
| Cash from operating activities | −$106.1M | −$122.9M | −$132.3M | −$248.2M | −$162.9M | −$39.2M | −$83.2M | −$38.6M | −$36.9M | −$29.8M |
| Investing activities | ||||||||||
| Capital expenditures | −$6.0M | −$730,000 | −$6.2M | −$35.6M | −$50.7M | −$4.9M | −$7.4M | −$2.3M | −$1.7M | −$457,000 |
| Investments (net) | $116.8M | $12.2M | $120.4M | $166.8M | −$273.3M | −$156.1M | −$150.1M | $1.8M | −$8.5M | −$3.7M |
| Acquisitions & other investing | $362,000 | $730,000 | −$1.6M | $35.6M | $0 | $0 | $0 | $0 | $0 | $18,000 |
| Cash from investing activities | $111.2M | $12.2M | $112.7M | $166.8M | −$324.0M | −$161.1M | −$157.5M | −$463,000 | −$10.2M | −$4.1M |
| Financing activities | ||||||||||
| Dividends paid | — | — | — | — | — | — | −$2.5M | — | −$15.2M | −$186,000 |
| Share repurchases & issuance (net) | — | — | — | — | $432.4M | $248.4M | $2.5M | $2.7M | −$193,000 | $186,000 |
| Net borrowing (repayment) | — | — | — | — | $0 | — | −$15.0M | −$15.0M | $4.2M | −$7.7M |
| Shares issued | $0 | $74.5M | $0 | $0 | $411.7M | $272.7M | $162.4M | $134.6M | $0 | $0 |
| Other financing | $5.5M | $25.4M | $85,000 | $9.2M | −$391.1M | −$238.3M | $2.5M | $18.5M | $58.6M | $65.4M |
| Cash from financing activities | $5.5M | $99.9M | $85,000 | $9.2M | $453.1M | $282.8M | $149.9M | $140.8M | $47.4M | $57.7M |
| Summary | ||||||||||
| Net change in cash | $10.6M | −$5.8M | −$19.5M | −$72.2M | −$33.8M | $67.5M | −$90.7M | $101.7M | $343,000 | $23.8M |
| Cash at end of period | $56.9M | $36.1M | $41.9M | $61.3M | $148.8M | $167.3M | $100.0M | $190.7M | $89.1M | $88.6M |
| Free cash flow | −$112.0M | −$123.6M | −$138.4M | −$283.8M | −$213.6M | −$44.2M | −$90.6M | −$41.0M | −$38.6M | −$30.3M |
| Free cash flow margin | −1,685.8% | −906.8% | −217.9% | −294.7% | −382.4% | −140.5% | −848.0% | −864.0% | −940.8% | −687.9% |
| Capex / revenue | 89.6% | 5.4% | 9.7% | 36.9% | 90.8% | 15.7% | 69.2% | 48.6% | 42.0% | 10.4% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$30.2M | −$31.2M | −$32.4M | −$32.2M | −$34.1M | −$37.6M | −$52.2M | −$47.7M | −$38.4M | −$48.0M | −$44.1M | −$45.2M |
| Depreciation & amortization | $2.8M | $2.9M | $3.1M | $3.2M | $3.3M | $3.3M | $4.8M | $4.6M | $4.7M | $4.8M | $4.9M | $4.7M |
| Stock-based compensation | $3.5M | $3.9M | $5.5M | $4.9M | $7.2M | $7.4M | $9.1M | $11.8M | $9.6M | $11.0M | $9.5M | $10.1M |
| Change in working capital | −$64,000 | −$6.0M | $1.1M | $504,000 | $73,000 | −$5.4M | −$1.9M | $3.1M | −$3.8M | $614,000 | −$189,000 | −$2.8M |
| Other non-cash items | $491,000 | −$492,000 | −$586,000 | −$716,000 | −$1.0M | −$1.5M | $12.3M | −$1.2M | −$4.4M | −$1.8M | −$6.7M | −$5.1M |
| Cash from operating activities | −$23.4M | −$30.8M | −$23.3M | −$24.4M | −$24.6M | −$33.8M | −$27.8M | −$29.4M | −$32.3M | −$33.4M | −$36.6M | −$38.3M |
| Investing activities | ||||||||||||
| Capital expenditures | −$80,000 | −$239,000 | −$1.2M | −$2.2M | −$1.4M | −$1.2M | −$98,000 | −$495,000 | −$51,000 | −$86,000 | −$181,000 | −$565,000 |
| Investments (net) | $14.6M | $23.8M | $28.6M | $21.3M | $19.6M | $42.7M | $22.8M | $25.5M | −$53.4M | $17.3M | $45.4M | $24.8M |
| Acquisitions & other investing | $0 | $0 | $237,000 | $2.2M | $1.4M | $1.2M | $98,000 | $495,000 | $51,000 | $86,000 | $181,000 | $565,000 |
| Cash from investing activities | $14.6M | $23.6M | $27.6M | $21.3M | $19.6M | $42.7M | $22.8M | $25.5M | −$53.4M | $17.3M | $45.4M | $24.8M |
| Financing activities | ||||||||||||
| Share repurchases & issuance (net) | — | — | — | — | — | — | −$666,000 | $666,000 | −$666,000 | — | −$180,000 | — |
| Shares issued | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $75.2M | $0 | $0 |
| Other financing | $1.7M | — | $1.7M | $2.5M | $1.3M | $0 | $3.8M | −$666,000 | $1.9M | $20.3M | $0 | $0 |
| Cash from financing activities | $1.7M | — | $1.7M | $2.5M | $1.3M | $0 | $3.1M | $0 | $1.3M | $95.5M | −$180,000 | $0 |
| Summary | ||||||||||||
| Net change in cash | −$7.1M | −$7.2M | $6.0M | −$627,000 | −$3.7M | $8.9M | −$1.9M | $992,000 | −$84.4M | $79.5M | $8.5M | −$13.5M |
| Cash at end of period | $42.5M | $49.6M | $56.9M | $50.8M | $51.5M | $55.1M | $46.3M | $37.9M | $52.1M | $136.5M | $41.9M | $48.5M |
| Free cash flow | −$23.5M | −$31.1M | −$24.5M | −$26.6M | −$25.9M | −$35.0M | −$27.9M | −$29.9M | −$32.4M | −$33.4M | −$36.8M | −$38.8M |
| Free cash flow margin | −1,129.4% | −2,391.1% | −1,790.1% | −1,526.5% | −1,360.7% | −2,148.9% | −1,499.8% | −973.1% | −477.8% | −1,736.9% | −2,196.8% | −1,997.8% |
| Capex / revenue | 3.8% | 18.4% | 87.1% | 126.5% | 71.4% | 73.4% | 5.3% | 16.1% | 0.8% | 4.5% | 10.8% | 29.1% |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
FATE cash generation
In fiscal 2025 (ended December 31, 2025), Fate Therapeutics generated -$106.1 million of cash from operations and spent $6.0 million on capital expenditures, leaving free cash flow of -$112.0 million, −1,685.8% of revenue. Cash and equivalents rose by $10.6 million over the year.
Related: FATE income statement, FATE balance sheet. See the FATE stock overview for the latest quote and news.
FATE cash flow FAQ
What is Fate Therapeutics's free cash flow?
Fate Therapeutics's free cash flow was -$112.0 million in fiscal 2025: -$106.1 million of operating cash flow minus $6.0 million of capital expenditures It was -$123.6 million a year earlier..
How much cash does Fate Therapeutics generate from operations?
Fate Therapeutics generated -$106.1 million of cash from operating activities in fiscal 2025.
How much does Fate Therapeutics spend on capital expenditures?
Fate Therapeutics spent $6.0 million on capital expenditures in fiscal 2025, 89.6% of revenue, compared with $0.7 million the year before.